The NSBCC administrative Core is described. The NSBCC is Directed by Jim Heath and co-Directed by Mike Phelps &Leroy Hood. Heath bears overall responsibility for the center, and specific responsibility for the technology development components. Dr. Hood bears specific responsibility for oversight of the biology (and systems biology) project components, and Dr. Phelps oversees the clinical translation of NSBCC projects. Each of the NSBCC leaders has extensive expertise in technology development, clinical translation, and technology commercialization. The NSBCC Leaders are guided by an Internal Review Council comprised of the Project Principal Investigators, and by an External Advisory Board. Descriptions of that guidance are provided. Rationale for how the scientific and personnel composition of the individual projects provide for a culture in which the sum of the components is greater than the parts is given - including a proven vision for accelerating the process of technology innovation to clinical demonstration. Significant partnerships with NCI funded programs, including the Jonsson Comprehensive Cancer Center, are described. Leverage from foundation funded programs and institutes, such as the Broad Institute for Regenerative Medicine, are discussed. Additional funding from foundation and other resources provides significant leverage for the NSBCC projects, and significantly accelerates our pathway into the clinic. Additional partnerships with for-profit companies (Sofie Biosciences, Integrated Diagnostics, and Momentum Biosciences) are described. Examples of how these partnerships are already leading to the commercial development of NSBCC technologies (from existing CCNE funding) are provided.
The NSBCC adminstration Core is designed to enable the success of our Projects, and to maximize the interaction of the NSBCC with the local oncology and cancer biology community. Internal and external oversight boards, meeting on a regular basis, provide guidance for steering NSBCC scientific programs and evaluating trans-Alliance and other opportunities as they arise.
|Hong, Candice Sun; Graham, Nicholas A; Gu, Wen et al. (2016) MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4. Cell Rep 14:1590-601|
|Poovathingal, Suresh Kumar; Kravchenko-Balasha, Nataly; Shin, Young Shik et al. (2016) Critical Points in Tumorigenesis: A Carcinogen-Initiated Phase Transition Analyzed via Single-Cell Proteomics. Small 12:1425-31|
|Henning, Ryan K; Varghese, Joseph O; Das, Samir et al. (2016) Degradation of Akt using protein-catalyzed capture agents. J Pept Sci 22:196-200|
|Clark, Andrew J; Wiley, Devin T; Zuckerman, Jonathan E et al. (2016) CRLX101 nanoparticles localize in human tumors and not in adjacent, nonneoplastic tissue after intravenous dosing. Proc Natl Acad Sci U S A 113:3850-4|
|Ghosh, Dhiman; Ulasov, Ilya V; Chen, LiPing et al. (2016) TGFÎ²-Responsive HMOX1 Expression Is Associated with Stemness and Invasion in Glioblastoma Multiforme. Stem Cells 34:2276-89|
|Wei, Wei; Shin, Young Shik; Xue, Min et al. (2016) Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma. Cancer Cell 29:563-73|
|Shin, Daniel Sanghoon; Ribas, Antoni (2015) The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? Curr Opin Immunol 33:23-35|
|Pan, Dorothy W; Davis, Mark E (2015) Cationic Mucic Acid Polymer-Based siRNA Delivery Systems. Bioconjug Chem 26:1791-803|
|Xue, Min; Wei, Wei; Su, Yapeng et al. (2015) Chemical methods for the simultaneous quantitation of metabolites and proteins from single cells. J Am Chem Soc 137:4066-9|
|Tanaka, Kazuhiro; Sasayama, Takashi; Irino, Yasuhiro et al. (2015) Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment. J Clin Invest 125:1591-602|
Showing the most recent 10 out of 50 publications